BioNTech SE stock: Oncology pivot amid revenue drop – buy now?

BioNTech faces a 25% revenue decline in 2026 while shifting to oncology, backed by €17.2B cash. This transition tests investor patience but offers long-term potential for global portfolios. ISIN: US09075V1026

You're watching BioNTech SE closely as it navigates a tough 2026, with forecasts showing a roughly 25% revenue drop to between €2.0 and €2.3 billion. The company, best known for its COVID-19 vaccine triumph with Pfizer, is now pivoting hard to oncology, closing facilities like its Singapore site and bracing for a net loss carryover from 2025's €1.14 billion hit. Yet with €17.2 billion in cash reserves, BioNTech has the runway to fund 15 Phase 3 oncology trials—making this a high-stakes moment for investors asking if now's the time to buy.

As of: 09.04.2026

By Elena Harper, Senior Biotech Equity Editor: BioNTech SE stands at a crossroads, transforming from vaccine leader to oncology innovator in a volatile biotech landscape.

BioNTech's Core Business and Post-Pandemic Shift

You know BioNTech SE as the German biotech that skyrocketed during the pandemic with its mRNA vaccine developed alongside Pfizer. That success generated massive revenues, but demand has plummeted, forcing a strategic overhaul. Now, the focus is squarely on oncology, where mRNA technology promises breakthroughs in cancer treatments like the lung cancer candidate gotistobart.

The company's pipeline includes promising assets such as BNT323 and BNT327, all advancing through clinical stages without expected commercial revenue in 2026. This shift involves restructuring, including closing the Singapore manufacturing site by February 2027, affecting 85 employees, to save up to $3 billion in costs. For you as an investor, this means BioNTech is pruning its vaccine-era excess to fuel cancer-fighting innovation.

Financially stable with €17.2 billion in liquidity at year-start, BioNTech can weather the revenue dip. Shares recently traded around €78 on European exchanges like Xetra and Tradegate, or about $92 on Nasdaq for ADRs, reflecting market caution amid the transition. You're right to wonder if this dip presents a buying opportunity or signals deeper risks.

Key Financials and 2026 Outlook

BioNTech reported a net loss of €1.14 billion in 2025, a stark contrast to pandemic highs, and management projects a 25% revenue decline for 2026. This forecast accounts for shrinking COVID-19 vaccine sales, with no oncology contributions yet. You can see why shares have slipped about 5.4% year-to-date and 11% over the past 30 days, trading near €78.

Despite headwinds, the balance sheet shines: €17.2 billion in cash provides multi-year funding for R&D. At the upcoming Annual General Meeting on May 15, 2026, shareholders will vote on key measures like a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH to offset losses tax-efficiently. New authorized capital up to 50% of current share capital ensures flexibility.

For U.S. investors trading ADRs on Nasdaq (around $92 recently), or Europeans on Xetra, this setup means BioNTech isn't running out of runway. The question for you is whether the cash hoard justifies holding through the dip or if execution risks warrant caution.

Oncology Pipeline: The Big Bet for Growth

BioNTech's future hinges on its oncology portfolio, with 15 Phase 3 trials planned by year-end. Candidates like gotistobart faced mixed Phase 1 data from the PRESERVE-003 trial in late March, prompting analyst scrutiny. Still, the mRNA platform, proven in vaccines, targets solid tumors with immunotherapies that could redefine cancer care.

You'll want to track readouts expected in 2026 for various cancer types, as success here could drive multi-billion revenues long-term. The company isn't banking on quick wins—no commercial oncology sales this year—but the pipeline depth offers diversification beyond vaccines. An FDA advisory committee meeting in May on COVID-19 vaccine compositions adds another layer, potentially stabilizing that segment.

This pivot positions BioNTech against giants like Merck and Bristol Myers Squibb in immuno-oncology. For global investors, the EU base and U.S. listings make it accessible, but trial outcomes will dictate if it's a buy or a pass.

Leadership Changes and Governance Evolution

Major shifts are underway: Founders Ugur Sahin and Özlem Türeci plan to depart by end-2026 to start a new venture, with successors in search. At the May 15 AGM, you'll see votes to expand the supervisory board from six to eight, nominating oncology experts Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich. This bolsters expertise in clinical development and commercialization.

These moves signal a professionalized post-founder era, critical for executing the oncology strategy. The virtual AGM formalizes the transformation, aligning governance with ambitions. For you, this reduces key-person risk but introduces uncertainty around new leadership execution.

U.S. tariffs announced April 2, 2026, could hit imports with up to 100% levies (capped at 15% for EU patented drugs), adding pressure. BioNTech's strong cash mitigates this, but it's a watchpoint for cross-Atlantic portfolios.

Analyst Views on BioNTech SE

Analysts offer a mixed but mostly positive outlook on BioNTech, with price targets varying widely amid the transition. Leerink Partners recently cut its target from $113 to $94, citing doubts on gotistobart data from the PRESERVE-003 trial's Phase 1 portion. Clear Street holds a Buy at $167, H.C. Wainwright at $130 post-trial data, and BMO Capital at $128, factoring in leadership changes.

These views from established firms reflect caution on near-term revenue but optimism for oncology upside. No consensus screams 'sell,' and the cash position reassures many. For you, this spread suggests doing your homework—targets imply upside from recent €78 / $92 levels, but execution is key.

BMO's adjustment highlights founder departures, yet maintains support. Overall, reputable banks see BioNTech's pivot as viable if trials deliver, making it a hold or accumulate candidate for patient investors.

Risks and What to Watch Next

Key risks include clinical setbacks, as seen with gotistobart, and prolonged vaccine demand weakness. Restructuring saves costs but signals pandemic-era overcapacity. New U.S. tariffs pose tariff risks for EU firms like BioNTech.

Watch the May 15 AGM for board votes and strategic updates, plus FDA meeting outcomes. Oncology data readouts in 2026 will be pivotal—success could spark rallies. For U.S., European, or global investors, monitor trial progress and leadership transitions closely.

BioNTech's €17.2B cash buys time, but dilution from authorized capital is possible. Volatility suits risk-tolerant portfolios chasing biotech growth.

Investor Takeaway: Buy, Hold, or Wait?

Should you buy BioNTech now? If you're patient and believe in mRNA oncology, the cash-backed dip could reward. Near-term pain from revenue drops and changes tempers enthusiasm—consider holding if owned, or waiting for trial catalysts. Global accessibility via Nasdaq ADRs or European exchanges fits diverse portfolios.

This matters to you amid biotech volatility: BioNTech exemplifies post-hype reinvention. Track oncology milestones and AGM outcomes next. With analysts split but upside potential, it's a calculated bet for growth seekers.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.